AMG-510 racemate is primarily utilized in the field of oncology research, particularly in the study of targeted cancer therapies. It is known for its role as a selective inhibitor of the KRAS G12C mutation, which is prevalent in certain types of cancers such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer. By inhibiting this mutation, AMG-510 racemate helps in blocking the signaling pathways that promote tumor growth and survival, making it a promising candidate for the development of effective cancer treatments.

Its application extends to preclinical studies where it is used to understand the mechanisms of KRAS-driven cancers and to evaluate the efficacy of potential therapeutic strategies. Additionally, it serves as a valuable tool in the development of combination therapies, where it may be used alongside other anticancer agents to enhance treatment outcomes.